• J Magn Reson Imaging · Feb 2010

    Randomized Controlled Trial Multicenter Study Comparative Study

    Enhancement of liver parenchyma after injection of hepatocyte-specific MRI contrast media: a comparison of gadoxetic acid and gadobenate dimeglumine.

    • Antonella Filippone, Anthony Blakeborough, Josy Breuer, Luigi Grazioli, Simone Gschwend, Renate Hammerstingl, Gertraud Heinz-Peer, Thomas Kittner, Andrea Laghi, Edward Leen, Riccardo Lencioni, Olivier Lucidarme, Philipp Remplik, Philip J Robinson, Stefan G Ruehm, Fritz Schaefer, Christoforos Stoupis, Bernd Tombach, Pierre-Jean Valette, Christoph J Zech, and Alexander Huppertz.
    • Department of Clinical Sciences and Bioimages, SS Annunziata Hospital, G. D'Annunzio University, Chieti, Italy. a.filippone@rad.unich.it
    • J Magn Reson Imaging. 2010 Feb 1; 31 (2): 356-64.

    PurposeTo compare enhancement of liver parenchyma in MR imaging after injection of hepatocyte-specific contrast media.Materials And MethodsPatients (n = 295) with known/suspected focal liver lesions randomly received 0.025 mmol gadoxetic acid/kg body weight or 0.05 mmol gadobenate dimeglumine/kg body weight by means of bolus injection. MR imaging was performed before and immediately after injection, and in the delayed phase at approved time points (20 min after injection of gadoxetic acid and 40 min after injection of gadobenate dimeglumine). The relative liver enhancement for the overall population and a cirrhotic subgroup was compared in T1-weighted GRE sequences. An independent radiologist performed signal intensity measurements. Enhancement ratios were compared using confidence intervals (CIs).ResultsThe relative liver enhancement in the overall population was superior with gadoxetic acid (57.24%) versus gadobenate dimeglumine (32.77%) in the delayed-imaging phase. The enhancement ratio between the contrast media was statistically significant at 1.75 (95% CI: 1.46-2.13). In the delayed phase, the enhancement of cirrhotic liver with gadoxetic acid (57.00%) was comparable to that in the overall population. Enhancement with gadobenate dimeglumine was inferior in cirrhotic liver parenchyma (26.85%).ConclusionIn the delayed, hepatocyte-specific phase, liver enhancement after injection of gadoxetic acid was superior to that obtained with gadobenate dimeglumine.

      Pubmed     Full text   Copy Citation     Plaintext  

      Add institutional full text...

    Notes

     
    Knowledge, pearl, summary or comment to share?
    300 characters remaining
    help        
    You can also include formatting, links, images and footnotes in your notes
    • Simple formatting can be added to notes, such as *italics*, _underline_ or **bold**.
    • Superscript can be denoted by <sup>text</sup> and subscript <sub>text</sub>.
    • Numbered or bulleted lists can be created using either numbered lines 1. 2. 3., hyphens - or asterisks *.
    • Links can be included with: [my link to pubmed](http://pubmed.com)
    • Images can be included with: ![alt text](https://bestmedicaljournal.com/study_graph.jpg "Image Title Text")
    • For footnotes use [^1](This is a footnote.) inline.
    • Or use an inline reference [^1] to refer to a longer footnote elseweher in the document [^1]: This is a long footnote..

    hide…

What will the 'Medical Journal of You' look like?

Start your free 21 day trial now.

We guarantee your privacy. Your email address will not be shared.